Elsevier
Journal of Clinical and Experimental Hepatology
,  volume 15 ,  issue 5 ,  pages 102563

Efficacy, Safety, and Tolerability of FXR Agonists in the Treatment of Metabolic dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis

Joel G.K. Mekontso 1
, 
Joseph Y. B. Nnang 2
, 
Ticha B.T. Tembi 3
, 
Anifatou B. Kortim 4
, 
Guy L. Nguefang 5
, 
Justin Wagner 1
, 
Michael Bernstein 1
1
 
New York City Health and Hospitals, South Brooklyn Health, Brooklyn, NY, USA | 
2
 
3
 
4
 
5
 
Publication type: Journal Article
Publication date: 2025-09-01
Elsevier
scimago Q2
wos Q2
SJR: 0.994
CiteScore: 5.1
Impact factor: 3.2
ISSN: 09736883, 22133453
Found 
Found 

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
2
Share
Cite this
GOST |
Cite this
GOST Copy
Mekontso J. G. et al. Efficacy, Safety, and Tolerability of FXR Agonists in the Treatment of Metabolic dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis // Journal of Clinical and Experimental Hepatology. 2025. Vol. 15. No. 5. p. 102563.
GOST all authors (up to 50) Copy
Mekontso J. G., Nnang J. Y. B., Tembi T. B., Kortim A. B., Nguefang G. L., Wagner J., Bernstein M. Efficacy, Safety, and Tolerability of FXR Agonists in the Treatment of Metabolic dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis // Journal of Clinical and Experimental Hepatology. 2025. Vol. 15. No. 5. p. 102563.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.jceh.2025.102563
UR - https://linkinghub.elsevier.com/retrieve/pii/S0973688325000635
TI - Efficacy, Safety, and Tolerability of FXR Agonists in the Treatment of Metabolic dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
T2 - Journal of Clinical and Experimental Hepatology
AU - Mekontso, Joel G.K.
AU - Nnang, Joseph Y. B.
AU - Tembi, Ticha B.T.
AU - Kortim, Anifatou B.
AU - Nguefang, Guy L.
AU - Wagner, Justin
AU - Bernstein, Michael
PY - 2025
DA - 2025/09/01
PB - Elsevier
SP - 102563
IS - 5
VL - 15
SN - 0973-6883
SN - 2213-3453
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2025_Mekontso,
author = {Joel G.K. Mekontso and Joseph Y. B. Nnang and Ticha B.T. Tembi and Anifatou B. Kortim and Guy L. Nguefang and Justin Wagner and Michael Bernstein},
title = {Efficacy, Safety, and Tolerability of FXR Agonists in the Treatment of Metabolic dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis},
journal = {Journal of Clinical and Experimental Hepatology},
year = {2025},
volume = {15},
publisher = {Elsevier},
month = {sep},
url = {https://linkinghub.elsevier.com/retrieve/pii/S0973688325000635},
number = {5},
pages = {102563},
doi = {10.1016/j.jceh.2025.102563}
}
MLA
Cite this
MLA Copy
Mekontso, Joel G.K., et al. “Efficacy, Safety, and Tolerability of FXR Agonists in the Treatment of Metabolic dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.” Journal of Clinical and Experimental Hepatology, vol. 15, no. 5, Sep. 2025, p. 102563. https://linkinghub.elsevier.com/retrieve/pii/S0973688325000635.